STF Management LP Sells 490 Shares of Moderna, Inc. (NASDAQ:MRNA)

STF Management LP lessened its stake in shares of Moderna, Inc. (NASDAQ:MRNA) by 8.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,527 shares of the company’s stock after selling 490 shares during the period. STF Management LP’s holdings in Moderna were worth $369,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Commerzbank Aktiengesellschaft FI lifted its holdings in Moderna by 1.7% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock valued at $660,000 after buying an additional 93 shares during the period. CVA Family Office LLC grew its position in shares of Moderna by 21.6% during the 2nd quarter. CVA Family Office LLC now owns 541 shares of the company’s stock valued at $64,000 after acquiring an additional 96 shares during the period. Claro Advisors LLC grew its position in shares of Moderna by 2.0% during the 2nd quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock valued at $659,000 after acquiring an additional 108 shares during the period. McAdam LLC lifted its stake in shares of Moderna by 1.1% during the 2nd quarter. McAdam LLC now owns 11,075 shares of the company’s stock valued at $1,315,000 after buying an additional 117 shares in the last quarter. Finally, 180 Wealth Advisors LLC lifted its stake in Moderna by 1.1% in the 2nd quarter. 180 Wealth Advisors LLC now owns 14,868 shares of the company’s stock worth $1,826,000 after purchasing an additional 160 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling at Moderna

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at approximately $682,754. This trade represents a 13.32 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 2,930 shares of company stock valued at $217,170. Company insiders own 15.70% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. Piper Sandler reissued an “overweight” rating and issued a $69.00 price target (down previously from $115.00) on shares of Moderna in a report on Monday. TD Cowen dropped their target price on shares of Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research report on Friday, September 13th. JPMorgan Chase & Co. dropped their target price on shares of Moderna from $70.00 to $59.00 and set an “underweight” rating for the company in a research report on Monday, November 4th. The Goldman Sachs Group lowered their price target on shares of Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research report on Monday, September 16th. Finally, Barclays lowered their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $84.00.

Moderna Trading Up 4.0 %

Shares of MRNA opened at $38.40 on Friday. Moderna, Inc. has a twelve month low of $35.80 and a twelve month high of $170.47. The company has a market cap of $14.78 billion, a P/E ratio of -6.60 and a beta of 1.69. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The company’s fifty day simple moving average is $56.13 and its 200-day simple moving average is $95.05.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.39) EPS. As a group, analysts expect that Moderna, Inc. will post -9.44 EPS for the current year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.